BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 32034238)

  • 1. Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma.
    Choi J; Kim SH; Ahn SS; Choi HJ; Yoon HI; Cho JH; Roh TH; Kang SG; Chang JH; Suh CO
    Sci Rep; 2020 Feb; 10(1):2086. PubMed ID: 32034238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of 1p/19q Codeletion in Diffuse Low-grade Glioma Tumour Prognosis.
    Familiari P; Lapolla P; Picotti V; Palmieri M; Pesce A; Carosi G; Relucenti M; Nottola S; Gianno F; Minasi S; Antonelli M; Frati A; Santoro A; D'Andrea G; Bruzzaniti P; LA Pira B
    Anticancer Res; 2023 Jun; 43(6):2659-2670. PubMed ID: 37247932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.
    Park YW; Kim S; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Kim SH; Lee SK; Chang JH
    Eur Radiol; 2024 Feb; 34(2):1376-1387. PubMed ID: 37608093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
    Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
    World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection.
    Nitta M; Muragaki Y; Maruyama T; Ikuta S; Komori T; Maebayashi K; Iseki H; Tamura M; Saito T; Okamoto S; Chernov M; Hayashi M; Okada Y
    Neurosurg Focus; 2015 Jan; 38(1):E7. PubMed ID: 25599276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.
    Santosh V; Rao S
    Indian J Pathol Microbiol; 2022 May; 65(Supplement):S14-S23. PubMed ID: 35562130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Factors for Progression Among Low-Grade Gliomas After Gross Total Resection and Initial Observation in the Molecular Era.
    Tom MC; Varra V; Leyrer CM; Park DY; Chao ST; Yu JS; Suh JH; Reddy CA; Balagamwala EH; Broughman JR; Kotagal KA; Vogelbaum MA; Barnett GH; Ahluwalia MS; Peereboom DM; Prayson RA; Stevens GHJ; Murphy ES
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1099-1105. PubMed ID: 31022510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrence patterns after maximal surgical resection and postoperative radiotherapy in anaplastic gliomas according to the new 2016 WHO classification.
    Im JH; Hong JB; Kim SH; Choi J; Chang JH; Cho J; Suh CO
    Sci Rep; 2018 Jan; 8(1):777. PubMed ID: 29335518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
    Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
    Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
    Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
    Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of surgery in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.
    Aghi MK; Nahed BV; Sloan AE; Ryken TC; Kalkanis SN; Olson JJ
    J Neurooncol; 2015 Dec; 125(3):503-30. PubMed ID: 26530265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60.
    Morshed RA; Han SJ; Hervey-Jumper SL; Pekmezci M; Troncon I; Chang SM; Butowski NA; Berger MS
    J Neurooncol; 2019 Jan; 141(2):383-391. PubMed ID: 30498891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
    Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D;
    Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system.
    Delev D; Heiland DH; Franco P; Reinacher P; Mader I; Staszewski O; Lassmann S; Grau S; Schnell O
    J Neurooncol; 2019 Jan; 141(1):223-233. PubMed ID: 30467813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
    J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
    Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
    J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.
    Ostrom QT; Shoaf ML; Cioffi G; Waite K; Kruchko C; Wen PY; Brat DJ; Barnholtz-Sloan JS; Iorgulescu JB
    Neuro Oncol; 2023 Apr; 25(4):799-807. PubMed ID: 35994777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of surgically treated low-grade gliomas: a retrospective analysis of a single institute.
    Turkoglu E; Gurer B; Sanli AM; Dolgun H; Gurses L; Oral NA; Donmez T; Sekerci Z
    Clin Neurol Neurosurg; 2013 Dec; 115(12):2508-13. PubMed ID: 24225484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival, Prognostic Factors, and Volumetric Analysis of Extent of Resection for Anaplastic Gliomas.
    Hong JB; Roh TH; Kang SG; Kim SH; Moon JH; Kim EH; Ahn SS; Choi HJ; Cho J; Suh CO; Chang JH
    Cancer Res Treat; 2020 Oct; 52(4):1041-1049. PubMed ID: 32324987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adult low-grade glioma: 19-year experience at a single institution.
    Youland RS; Brown PD; Giannini C; Parney IF; Uhm JH; Laack NN
    Am J Clin Oncol; 2013 Dec; 36(6):612-9. PubMed ID: 22892428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.